Equasym XL 30 mg

Equasym XL is an extended-release stimulant medication containing methylphenidate hydrochloride, primarily used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD). The 'XL' designation signifies a dual-release formulation (30% immediate and 70% modified release).

The brand was originally developed by pharmaceutical companies in Europe, notably within the portfolios of companies like UCB and Shire. Today, the brand is owned and distributed by Takeda Pharmaceuticals, a leading global biopharmaceutical company headquartered in Japan, following their acquisition of Shire in 2019. Manufacturing for these specialized capsule formulations often takes place in Ireland, which is a major global hub for Takeda’s pharmaceutical production, though distribution is handled via local subsidiaries worldwide.